Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA Highlights Mavenclad Advances In Tough Quarter

Executive Summary

Merck KGaA's brace of new products started to garner sales in the third quarter, but the big pharma maintained its 2017 guidance at the lower end of the forecast range in the face of increasing competition to its established pharmaceutical products and to its liquid crystal materials, and currency headwinds.

Advertisement

Related Content

Executive Interview: Building Merck KGaA's Specialty Business In EMEA
Don’t Miss The Train: Pharma's Future Holds Deeper Digital Deals, Outcome-Based Pacts
Merck KGaA Says Outcomes-Based Pact With NHS England 'Precedent-Setting'
PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride
Merck KGaA Rules Out Major M&A, Says MS Pill Mavenclad Will Be Major Earner
Merck KGaA's MS Drug Mavenclad May Defy Doubters

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel